Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Impact · against what's priced in

The continuing securities fraud investigations into ALNY, TTAN, and GEHC are largely noise for investors. For ALNY and GEHC, the underlying operational failures and legal risks are already factored into the current valuations.

ALNY−0.05

Already priced in

The price assumes

A $200 million cut to 2026 TTR product revenue guidance